This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.
Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down
by Zacks Equity Research
Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
Q2 Earnings Drive Pharma ETFs Higher
by Sweta Killa
The string of strong results pushed pharma ETFs higher, with the four funds posting positive returns over the past one month.
Zacks Investment Ideas feature highlights: Merck and Amgen
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Merck and Amgen
Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Aduro's loss (ADRO) betters estimates in Q2. However, lower license and collaboration fees induce a slight dip in year-over-year revenues.
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval
by Zacks Equity Research
Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.
PFE vs. MRK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PFE vs. MRK: Which Stock Is the Better Value Option?
Dow 30 Stock Roundup: Apple, DowDuPont, Caterpillar, Pfizer Earnings Impress
by Swarup Gupta
The index endured a difficult week, marked by a decline in tech stocks and trade war fears.
Two Pharma Giants Successfully Navigate a Challenging Climate
by David Borun
Amgen and Merck rely on a wide range of profitable drugs to produce steady profits
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss and beats revenue estimates in the second quarter of 2018.
Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2
by Zacks Equity Research
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.
Incyte (INCY) Earnings Miss, Revenues Beat Estimates in Q2
by Zacks Equity Research
Incyte's (INCY) Q2 results were a mixed bag with earnings missing estimates, while revenues beating the same with growth in Jakafi's sales. A milestone payment from Eli Lilly boosted sales as well.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Ups Profit View
by Zacks Equity Research
Pfizer (PFE) beats expectations for earnings as well as sales in the second quarter. It raises earnings expectations for 2018 but slightly lowers the sales range.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.
Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod
by Zacks Equity Research
Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates as well as rides high on revenue beat in Q2.
Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength
by Zacks Equity Research
Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
Merck (MRK) Tops on Q2 Earnings & Sales, Stock Up
by Zacks Equity Research
Merck (MRK) beat estimates for both earnings and sales in second quarter. It raises earnings guidance while tightens sales expectations for 2018. Stock is up in pre-market trading.
Merck (MRK) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 2.91% and 1.45%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Must-See Earnings Charts to End the Week
by Tracey Ryniec
There's more earnings excitement still to come as many investor favorites report.
AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.
ABBV, MRK Q2 Earnings on Jul 27: Here are the Key Predictions
by Zacks Equity Research
The pharma/biotech industry has witnessed a solid start in the Q2 reporting cycle. Let's see if leading players - Merck (MRK) and AbbVie (ABBV) - can contribute further to the encouraging numbers.
Merck's Keytruda Improves Survival in Head/Neck Cancer Study
by Zacks Equity Research
Merck's (MRK) key cancer drug Keytruda succeeds as a monotherapy in phase III program. It is being evaluated for the first-line treatment of patients with advanced head and neck cancer.